Jiao Wang

Jiao Wang


Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
Verified
Journal Article
Open access
PDF file
XHxiudan han
xiudan han
JWJiao Wang
Jiao Wang
RLRuilin Li
Ruilin Li
MHMeiling Huang
Meiling Huang
GYGuanru Yue
Guanru Yue
JXJi-Xiong Xu
Ji-Xiong Xu
The use of mesenchymal stem cells (MSCs) has become a new strategy for treating diabetic kidney disease (DKD). However, the role of placenta derived mesenchymal stem cells (P-MSCs) in DKD remains unclear. This study aims to investigate the therapeutic application and molecular mechanism of P-MSCs on DKD from the perspective of podocyte injury and PINK1/Parkin-mediated mitophagy at the animal, cellular, and molecular levels. Western blotting, reverse transcription polymerase chain reaction, immunofluorescence, and immunohistochemistry were used to detect the expression of podocyte injury-related markers and mitophagy-related markers, SIRT1, PGC-1α, and TFAM. Knockdown, overexpression, and rescue experiments were performed to verify the underlying mechanism of P-MSCs in DKD. Mitochondrial function was detected by flow cytometry. The structure of autophagosomes and mitochondria were observed by electron microscopy. Furthermore, we constructed a streptozotocin-induced DKD rat model and injected P-MSCs into DKD rats. Results showed that as compared with the control group, exposing podocytes to high-glucose conditions aggravated podocyte injury, represented by a decreased expression of Podocin along with increased expression of Desmin, and inhibited PINK1/Parkin-mediated mitophagy, manifested as a decreased expression of Beclin1, the LC3II/LC3I ratio, Parkin, and PINK1 associated with an increased expression of P62. Importantly, these indicators were reversed by P-MSCs. In addition, P-MSCs protected the structure and function of autophagosomes and mitochondria. P-MSCs increased mitochondrial membrane potential and ATP content and decreased the accumulation of reactive oxygen species. Mechanistically, P-MSCs alleviated podocyte injury and mitophagy inhibition by enhancing the expression of the SIRT1-PGC-1α-TFAM pathway. Finally, we injected P-MSCs into streptozotocin-induced DKD rats. The results revealed that the application of P-MSCs largely reversed the markers related to podocyte injury and mitophagy and significantly increased the expression of SIRT1, PGC-1α, and TFAM compared with the DKD group. In conclusion, P-MSCs ameliorated podocyte injury and PINK1/Parkin-mediated mitophagy inhibition in DKD by activating the SIRT1-PGC-1α-TFAM pathway.

18 September 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
JWJiao Wang
Jiao Wang
HLHonghong Liu
Honghong Liu
GYGuanru Yue
Guanru Yue
YDYuanyuan Deng
Yuanyuan Deng
WCWei Cai
Wei Cai
JXJi-Xiong Xu
Ji-Xiong Xu

14 February 2025 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Closed access
YZYun Zou
Yun Zou
MZMengyao Zhuo
Mengyao Zhuo
WCWen Chen
Wen Chen
WSWenze Song
Wenze Song
YJYanxia Jiang
Yanxia Jiang
JWJiao Wang
Jiao Wang

14 January 2026 in Biomedicines
Verified
Journal Article
Open access
PDF file
WSWenze Song
Wenze Song
JWJiao Wang
Jiao Wang
LGLulu Guan
Lulu Guan
YZYun Zou
Yun Zou
JXJixiong Xu
Jixiong Xu
WCWei Cai
Wei Cai
Objective: Diabetic kidney disease (DKD) is characterized by podocyte injury and impaired autophagy. Bone marrow mesenchymal stem cell-derived exosomes (BMSC-Exos) exhibit therapeutic potential for DKD, yet their mechanisms remain unclear. This study investigated whether BMSC-Exos restore podocyte autophagy via the miR-143-3p/Bcl-2/Beclin1 axis to delay DKD progression. Methods: A high-glucose (HG)-induced podocyte injury model was established using mouse podocytes (MPC5). Autophagy-related proteins (Beclin1, Bcl-2, LC3) and the injury marker desmin were analyzed by Western blot and immunofluorescence (IF). High-throughput sequencing identified BMSC-Exos-enriched miRNAs, with the miR-143-3p/Bcl-2 targeting relationship validated by dual-luciferase reporter assays. BMSCs transfected with miR-143-3p mimic or inhibitor were used to assess exosomes effects on autophagy and podocin expression. In vivo, DKD mice received tail vein injections of modified BMSC-Exos, followed by evaluation of physiological parameters, biochemical indices, and renal histopathology. Results: BMSC-Exos were successfully isolated and characterized. Fluorescence microscopy confirmed exosomes internalization by HG-treated MPC5 cells. BMSC-Exos upregulated Beclin1 and LC3-II while downregulating Bcl-2 and desmin, indicating enhanced autophagy. High-throughput sequencing revealed miR-143-3p enrichment in BMSC-Exos, and Bcl-2 was confirmed as a direct target of miR-143-3p. Exosomes from miR-143-3p mimic-transfected BMSCs further promoted autophagy and podocin expression. In DKD mice, BMSC-Exos reduced blood glucose, urinary albumin-to-creatinine ratio (UACR), and ameliorated renal damage, whereas miR-143-3p inhibition attenuated these effects. Conclusions: BMSC-Exos deliver miR-143-3p to target Bcl-2, thereby activating Beclin1-mediated autophagy and ameliorating DKD. This study elucidates a novel autophagy regulatory mechanism supporting BMSC-Exos as a cell-free therapy for DKD.

8 November 2022 in Frontiers in Physiology
Verified
Journal Article
Open access
ZZZhenguo Zeng
Zhenguo Zeng
KZKang Zou
Kang Zou
CQChen Qing
Chen Qing
JWJiao Wang
Jiao Wang
YTYunliang Tang
Yunliang Tang
Background: Patients with severe acute kidney injury (AKI) require continuous renal replacement therapy (CRRT) when hemodynamically unstable. We aimed to identify prognostic factors and develop a nomogram that could predict mortality in patients with AKI undergoing CRRT.Methods: Data were extracted from the Dryad Digital Repository. We enrolled 1,002 participants and grouped them randomly into training (n = 670) and verification (n = 332) datasets based on a 2:1 proportion. Based on Cox proportional modeling of the training set, we created a web-based dynamic nomogram to estimate all-cause mortality.Results: The model incorporated phosphate, Charlson comorbidity index, body mass index, mean arterial pressure, levels of creatinine and albumin, and sequential organ failure assessment scores as independent predictive indicators. Model calibration and discrimination were satisfactory. In the training dataset, the area under the curves (AUCs) for estimating the 28-, 56-, and 84-day all-cause mortality were 0.779, 0.780, and 0.787, respectively. The model exhibited excellent calibration and discrimination in the validation dataset, with AUC values of 0.791, 0.778, and 0.806 for estimating 28-, 56-, and 84-day all-cause mortality, respectively. The calibration curves exhibited the consistency of the model between the two cohorts. To visualize the results, we created a web-based calculator.Conclusion: We created a web-based calculator for assessing fatality risk in patients with AKI receiving CRRT, which may help rationalize clinical decision-making and personalized therapy.

16 October 2025 in Diabetes
Verified
Journal Article
Closed access
WCWen Chen
Wen Chen
JLJiarong Liu
Jiarong Liu
YZYun Zou
Yun Zou
FLFang Lu
Fang Lu
JZJunping Zhang
Junping Zhang
JWJiao Wang
Jiao Wang
Diabetic kidney disease (DKD) progression involves NIMA-related kinase 7 (NEK7)–driven podocyte pyroptosis, with hyperglycemia-induced O-GlcNAcylation as a key posttranslational regulator. This study elucidates how O-GlcNAc modification governs NEK7 stability and its pathological role. We used clinical DKD specimens, high-glucose–stimulated podocytes, and streptozotocin-induced diabetic mice to first examine NEK7, O-GlcNAc, O-GlcNAc transferase (OGT), and glutamine fructose-6-phosphate amidotransferase 1 (GFPT1) expression, confirming the pyroptosis role of NEK7 via siRNA knockdown. Bioinformatic analysis predicted O-GlcNAcylation motifs, validated by T302A mutagenesis and coimmunoprecipitation. Protein stability was assessed using cycloheximide chase and ubiquitination assays. Therapeutic efficacy of the GFPT1 inhibitor (6-diazo-5-oxo-l-norleucine) DON was evaluated in vitro and in vivo through biochemical parameters, histopathology, and pyroptosis markers. Chronic hyperglycemia activated the hexosamine biosynthetic pathway (HBP), elevating pathology-associated O-GlcNAc modifications that promoted NEK7 accumulation via posttranslational stabilization. This was accompanied by upregulated O-GlcNAc, OGT, and GFPT1 in DKD glomeruli and high-glucose podocytes. Crucially, threonine 302 was identified as the primary O-GlcNAcylation site of NEK7. This modification reduced proteasomal degradation, extended NEK7 half-life, and enhanced NLRP3 inflammasome activation and interleukin release. Pharmacological HBP inhibition using DON normalized O-GlcNAcylation, suppressed pyroptosis, and mitigated renal injury. We report the discovery of the glucose/O-GlcNAc/NEK7/NLRP3 axis driving podocyte pyroptosis in DKD, proposing threonine 302 as a potential therapeutic target. These findings establish a novel posttranslational modification mechanism and suggest a dual-target therapeutic strategy for DKD management. Article Highlights: We identify threonine 302 as the critical O-GlcNAcylation site on NIMA-related kinase 7 (NEK7), which stabilizes NEK7 by inhibiting its proteasomal degradation, thereby enhancing NLRP3 inflammasome activation and podocyte pyroptosis in diabetic kidney disease (DKD). Chronic hyperglycemia activates the hexosamine biosynthetic pathway (HBP), driving pathological O-GlcNAcylation and significant upregulation of NEK7, O-GlcNAc transferase, and glutamine fructose-6-phosphate amidotransferase 1 in glomeruli from patients with DKD and experimental models. This study establishes the discovery of the pathogenic glucose/O-GlcNAc/NEK7/NLRP3 signaling axis, identifying a novel posttranslational mechanism driving podocyte loss in DKD progression. Pharmacological inhibition of the HBP with 6-diazo-5-oxo-l-norleucine normalizes O-GlcNAcylation, suppresses NEK7-driven pyroptosis, and mitigates renal injury, demonstrating the therapeutic potential of targeting threonine 302, NEK7, or the HBP for DKD management.